MEDICLINIC INTERNATIONAL PLC - Mediclinic half-year results for the six months ended 30 September 2022

Mediclinic half-year results for the six months ended 30 September 2022

Mediclinic International plc
Incorporated in England and Wales
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
South African income tax number: 9432434182
('Mediclinic', or the 'Company', or the 'Group')

MEDICLINIC HALF-YEAR RESULTS FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2022

GROUP FINANCIAL RESULTS

    -   Group revenue increased by 10% compared with 1H22 (up 2% in constant currency)
    -   Group adjusted EBITDA decreased by 1% compared with 1H22 (down 8% in constant
        currency), with an adjusted EBITDA margin of 14.2% (1H22: 15.8%), reflecting revenue impact
        and increased operating expenses
    -   Adjusted operating profit of £131m decreased by 11% compared with 1H22 (down 20% in
        constant currency)
    -   Operating profit down 8% to £119m (1H22: £129m)
    -   Adjusted earnings and adjusted earnings per share decreased by 15% compared with 1H22
    -   Reported earnings up 28% to £83m (1H22: £65m) and reported earnings per share up 28% to
        11.3 pence (1H22: 8.8 pence)
    -   Headline earnings per share 11.3 pence (1H22: 8.8 pence)
    -   Operating performance and cash conversion of 72% (1H22: 104%) delivered cash and cash
        equivalents to £445m (FY22: £534m)
    -   Leverage ratio (including lease liabilities) at 4.4x (FY22: 3.9x), reflecting foreign exchange
        translation differences and lower cash conversion
    -   No interim dividend proposed in light of current offer for Mediclinic by Manta Bidco Limited
        ('Bidco') (a newly formed company owned by joint offerors: [i] Remgro Limited ['Remgro']
        [through certain subsidiaries]; and [ii] SAS Shipping Agencies Services S.à r.l. ['SAS'], a
        wholly owned subsidiary of MSC Mediterranean Shipping Company SA)

FURTHER INFORMATION

The contents of this short-form announcement is the responsibility of the Board of Directors of the
Company. This announcement represents a summary of the information contained in the unabridged
results announcement. Any investment decisions by investors and/or shareholders should be based
on a consideration of the unabridged announcement. The unabridged announcement can be
accessed on the following JSE link:

https://senspdf.jse.co.za/documents/2022/JSE/ISSE/MEIE/MEIHY23.pdf

The announcement is also published on www.mediclinic.com and available for inspection at the
registered office of the Company and the offices of the Company's sponsor at no charge, during
normal business hours.

CORPORATE INFORMATION

LISTINGS
The Company's primary listing is on the London Stock Exchange in the United Kingdom, with
secondary listings on the JSE in South Africa and the Namibian Stock Exchange in Namibia.
                                     
DIRECTORS
Inga Beale DBE (ind ne) (Chair) (British), Dr Ronnie van der Merwe (Group Chief Executive Officer)
(South African), Jurgens Myburgh (Group Chief Financial Officer) (South African), Dr Felicity Harvey
CBE (Senior Independent Director) (British), Dr Muhadditha Al Hashimi (ind ne) (Emirati), Natalia
Barsegiyan (ind ne) (French and Russian), Zarina Bassa (ind ne) (South African), Jannie Durand (ne)
(South African), Danie Meintjes (ne) (South African), Dr Anja Oswald (ind ne) (Swiss), Tom Singer
(ind ne) (British), Steve Weiner (ind ne) (American), Pieter Uys (alternate to Jannie Durand) (South
African)

COMPANY SECRETARY
Link Company Matters Limited (previously named Capita Company Secretarial Services Limited)

REGISTERED OFFICE
Mediclinic International plc
6th Floor, 65 Gresham Street
London, EC2V 7NQ, United Kingdom
Tel: +44 333 300 1930
Email: info@mediclinic.com
Website: www.mediclinic.com

TOLL-FREE ETHICS LINES AND EMAIL
Switzerland
Tel: 0800 005 316
South Africa
Tel: 0800 005 316
Namibia
Tel: 0800 003 313
MTC Networks: 081 91847
The United Arab Emirates
Tel: 800 1 55000

Email: mediclinic@tip-offs.com

REGISTRAR/TRANSFER SECRETARIES
UK
United Kingdom Computershare Investor Services PLC
SOUTH AFRICA
Computershare Investor Services (Pty) Ltd
NAMIBIA
Transfer Secretaries (Pty) Ltd

CORPORATE ADVISORS

AUDITOR
PricewaterhouseCoopers LLP, London

CORPORATE BROKER AND SPONSORS
UK
Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank
South Africa
JSE sponsor: Rand Merchant Bank (a division of FirstRand Bank Limited)
Namibia
NSX sponsor: Simonis Storm Securities (Pty) Ltd

APPROVED BY THE BOARD: 15 November 2022

SENS RELEASE DATE: 16 November 2022



                                         

Date: 16-11-2022 09:00:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.